Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Sclar

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Journal of Attention Disorders|February 4, 2017
Diagnosis and Treatment of ADHD in the United States: Update by Gender and RaceKathleen A Fairman, Alyssa M Peckham, David A Sclar
Risk Management and Healthcare Policy|August 30, 2018
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceAlyssa M Peckham, Maria J Ananickal, David A Sclar
Psychiatric Services (Washington, D.C.)|December 13, 2005
Datapoints: trends in ADHD and stimulant use among adults: 1995-2002Linda M Robison, David A Sclar, Tracy L Skaer
BMJ (Clinical Research Ed.)|December 2, 2017
Call for increased pharmacovigilance of gabapentinAlyssa M Peckham, Kathleen A Fairman, David A Sclar
Clinical Drug Investigation|April 29, 2017
Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US PopulationAlyssa M Peckham, Kathleen A Fairman, David A Sclar
International Clinical Psychopharmacology|February 28, 2008
Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United StatesDavid A Sclar, Linda M Robison, Tracy L Skaer
The Diabetes Educator|November 15, 2006
Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?Tracy L Skaer, David A Sclar, Linda M Robison
Drug, Healthcare and Patient Safety|May 16, 2018
Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visitsKyle C Molina, Kathleen A Fairman, David A Sclar
General Hospital Psychiatry|January 1, 2008
Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?David A Sclar, Linda M Robison, Corrine Gavrun, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|September 13, 2008
Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007Chi-Chuan Wang, Jae Kennedy, Lawrence J Cohen, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Journal of Attention Disorders|February 4, 2017
Diagnosis and Treatment of ADHD in the United States: Update by Gender and RaceKathleen A Fairman, Alyssa M Peckham, David A Sclar
Risk Management and Healthcare Policy|August 30, 2018
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceAlyssa M Peckham, Maria J Ananickal, David A Sclar
Psychiatric Services (Washington, D.C.)|December 13, 2005
Datapoints: trends in ADHD and stimulant use among adults: 1995-2002Linda M Robison, David A Sclar, Tracy L Skaer
BMJ (Clinical Research Ed.)|December 2, 2017
Call for increased pharmacovigilance of gabapentinAlyssa M Peckham, Kathleen A Fairman, David A Sclar
Clinical Drug Investigation|April 29, 2017
Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US PopulationAlyssa M Peckham, Kathleen A Fairman, David A Sclar
International Clinical Psychopharmacology|February 28, 2008
Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United StatesDavid A Sclar, Linda M Robison, Tracy L Skaer
The Diabetes Educator|November 15, 2006
Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?Tracy L Skaer, David A Sclar, Linda M Robison
Drug, Healthcare and Patient Safety|May 16, 2018
Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visitsKyle C Molina, Kathleen A Fairman, David A Sclar
General Hospital Psychiatry|January 1, 2008
Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?David A Sclar, Linda M Robison, Corrine Gavrun, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|September 13, 2008
Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007Chi-Chuan Wang, Jae Kennedy, Lawrence J Cohen, et al.
Pageof 6